23 September 2025 in Blood Advances
Multiple myeloma (MM) relapsing after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell treatment remains a therapeutic challenge. Data on re-exposure to CAR T-cell therapy targeting the same antigen are scarce. We analyzed 10 heavily pretreated patients with RRMM at 3 medical centers treated with the commercially approved CAR T-cell therapy product idecabtagene vicleucel in a real-world setting. Upon relapse, all patients received ciltacabtagene autoleucel as a second CAR T-cell therapy infusion, with bridging treatments permitted between both therapies. Sequential therapy with BCMA-directed CAR T-cell therapy was safe, with no higher-grade immune-cell–associated side effects or new safety signals. We found robust CAR T-cell therapy expansion and high response rates (100% with at least very good partial response, with 60% achieving minimal residual disease negativity), with an estimated progression-free survival of 64.8% (95% confidence interval, 39%-100%) at 6 months after the second CAR T-cell treatment. Duration of response to first CAR T-cell therapy was predictive for durable responses to the second CAR T-cell therapy product. Loss of BCMA antigen occurred in only 1 of 3 patients relapsing after ciltacabtagene autoleucel. Two of three relapsing patients died within a year, and showed no further response to bispecific antibody treatment. To our knowledge, this study provides the first real-world evidence that sequential treatment with 2 different commercially approved BCMA CAR T-cell therapy products is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR T-cell therapy.
1 April 2026 in Blood Advances
Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19–directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 × 106 and DL2, 2.5 × 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome of grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.
18 September 2026 in Blood Advances
DUDébora-Michèle Grote Urtubey
Débora-Michèle Grote Urtubey
+59
For patients with large B-cell lymphoma progressing after multiple lines of therapy few treatment options remain, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pre-treated patients received lonca in third and later line of therapy. 76% had received treatment with chimeric antigen receptor T-cells (n=55), bispecific antibodies (BsAbs) (n=56) or both (n=40). The overall response rate was 27% and complete response rate was 10%. Median progression-free (mPFS) and overall survival (mOS) were 2.2 and 4.4 months, respectively. Median PFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥ 3 infections (13%) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly better than the remaining non-consolidated patients (mOS: 15.2 vs. 3.8 months, p=0.048). In multivariable analysis, no response to the last therapy prior to lonca (OS - HR: 2.5, p=0.014) and secondary IPI (PFS/OS - HR: ≥2.0, p≤0.024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. While enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.